

CLAIMS

1. (Withdrawn) A method of medical treatment of devastating effects against a human immunodeficiency virus and an acquired immunodeficiency syndrome by using a medication with any of a natural and synthetic capsaicin, related derivatives, vanilloids and capsicum extract comprising:

- (a) providing an intravenous, intramuscular /subcutaneous and digestive treatments with said medication, and
- (b) providing an intramuscular / subcutaneous pretreatment previous to said intravenous treatment making permissible an administration of said medication by this way in a human body, and
- (c) providing an independent and combined administration of the substance, through a periodic and subsequent application of said treatments means according to a different stage of said diseases in a patient, and

whereby said intravenous treatment will produce, a neuropeptide release in humans, stimulating it a immune system, a virus replication inhibition and a control of opportunistic diseases related, and,

whereby said intramuscular / subcutaneous treatment will serve as an alternative treatment to said intravenous treatment, and

whereby said intramuscular /subcutaneous pretreatment will minimize a bezold-jarisch reflex by reducing a side effect of said medication, and

whereby said digestive treatment will provoke an antioxidant effect and it will also help to control opportunistic diseases related, specially it that attacks a digestive system.

2. (Withdrawn) A method of medical treatment of claim 1, wherein said treatments are applied, comprising:

- (a) administration of said medication following it a pattern according to a function of values of x equal to $1/x$, where a value of x is bigger than 0, in agreement to figures 2, 3 and 4, and

- (b) administration of said medication, wherein said treatments are equivalents by means a potency of the substance, and
 - (c) administration of said medication following said function and a predetermined range of concentrations and doses defined upon an aside of concentrations and dosage, and
 - (d) administration of said medication, wherein said predetermined range of concentrations is limited between a concentration that provokes a sensation of perceptible warmth and a concentration not reaching it a sensation of persistent burning, and
 - (e) administration of said medication by increasing a dose and a concentration in said predetermined range, means for inducing a light nervous desensitization process in the human organism, and
 - (f) administration of said medication by regulating a velocity of injecting at least at 1ml/min for a first half of medications and at 1ml/30sec for a remainder of medications.
3. (Withdrawn) A method of medical treatment of claim 2, wherein said predetermined range of concentrations and doses is defined comprising:
- (a) providing an intravenous administration of said medication, through a range of concentrations between 2mcg/ml and 8mcg/ml, and a range of doses between 1mcg/kg and 7mcg/kg of body weight, and
 - (b) providing an intramuscular / subcutaneous administration of said medication, through a range of concentrations between 10mcg/ml and 80mcg/ml, and a range of doses between 1mcg/kg and 8mcg/kg of bodyweight, and
 - (c) providing a digestive administration of said medication, through a range of concentrations between 100mcg/gr and 450mcg/gr, and a range of doses between 100mcg/kg and 450mcg/kg of bodyweight.
4. (Withdrawn) A method of medical treatment of claim 1, wherein said treatments are applied by leaving a patient period of resting comprising:
- (a) of at least thirty consecutive days among said treatments, and
 - (b) of at least a day off among two different doses.

5. (Withdrawn) A method of medical treatment of claim 1, where said treatments are applied, comprising:

- (a) a duration of twenty six days for said intravenous treatment by applying a maximum of thirteen doses, and
- (b) a duration of thirty days for said intramuscular /subcutaneous and digestive treatments by applying a maximum of fifteen doses in each of one, and
- (c) a duration of three days for said intramuscular / subcutaneous pretreatment.

6. (Withdrawn) A method of medical treatment of claim 1, wherein an administration of said medication for the intramuscular / subcutaneous pretreatment is defined, comprising:

- (a) providing a concentration and dose of said medication which they are equivalents respectively to a first concentration and dose of said intravenous treatment, and
- (b) providing the administration of said medication being defined for a total dose at 10mcg/kg of body weight, which is ten times bigger than said first dose of said intravenous treatment, which is at 1mcg/kg of the bodyweight, and
- (c) extending the administration of said medication on a same injecting area to apply said intravenous treatment by administering, 2mcg/kg of bodyweight in a first day, 3mcg/kg in a second day and 5mcg/kg in a third day, and
- (d) providing the administration of said medication by applying a concentration at 20mcg/ml in the first day, 30mcg/ml in the second day and 50mcg/ml in the third day.

7. (Withdrawn) A method of medical treatment of claim 1, further including administration of said medication by topical treatment and systemic effect of absorption, using same doses and concentrations of said intramuscular and subcutaneous treatment as shown upon the aside of concentrations and doses.

8. (Withdrawn) A method of medical treatment of claim 1, wherein said immune system stimulation and a effectiveness of the substance is monitored through a test of lymphocytes t4 to observe a clinical progression of said diseases and its response to said concentrations and doses of the medication.

9. (Cancelled) A fabrication and use of a medication by including an active substance such as any a natural and synthetic capsaicin, against a human immunodeficiency virus and an acquired immunodeficiency syndrome, comprising:

- (a) fabrication and use of said medication by including any of said natural capsaicin, according to a chemical formulate, showed in the fig 1a, and
- (b) fabrication and use of a pharmaceutical carrier solution containing, an alcobol denominated ethanol ranging it between 5 and 10% v/v as preferred diluent, and said alcohol with less than 5% v/v as more preferred diluent, and
- (c) fabrication and use of said pharmaceutical carrier solution by adding an emulsifier and stabilizer denominated polyoxyenthylenesorbitan monooleate, also called tween.rtm.80 ranging it between 5 and 10% v/v, and
- (d) fabrication and use of said pharmaceutical carrier solution by finally adding to complete a volume of the medication with a distilled water as preferred second diluent, and a saline isotonic solution with 0.9% of sodium chloride as more preferred second diluent, and
- (e) fabrication and use of said medication by elaborating an infuse of high volume for an intravenous treatment, and an infuse of low volume for an intramuscular / subcutaneous treatment and intramuscular / subcutaneous pretreatment.

10. (Cancelled) A fabrication and use of the medication of claim 9, wherein a procedure for manufacturing an intravenous first infuse is taken as example to elaborate a rest of infuses comprising:

- (a) elaboration of 1 liter of a prime solution by using a amount of 1gr of any of said natural and synthetic capsaicin, and 5% v/v of said diluent, which are mixed until said active substance is dissolved obtaining a solution which it is agitated, and
- (b) adding a amount of 10% v/v of said emulsifier to said solution until the active principle is evenly dispersed, and adding 85% v/v of a distilled water to complete a volume of the resulting prime solution which it is agitated , and
- (c) elaboration of a carrier solution by mixing 5% v/v of said diluent, 10% v/v of said emulsifier and 85% v/v of said second diluent which it is agitated, and

- (d) taking 3ml of said resulting prime solution and diluting it in 997ml of said carrier solution to obtain a concentration approximately at 3mcg/ml and submitting such an infuse solution to a test of high performance liquid chromatography to determine and verify an exact concentration, and
 - (e) increasing a volume of said infuse solution by using said carrier solution to rectify a concentration at 2mcg/ml for obtaining a final infuse solution, and
 - (f) extracting a required volume from said final infuse solution according to an intravenous first dose at 1mcg/kg bodyweight of a patient, and
 - (g) fabricating a remainder of the intravenous and intramuscular /subcutaneous infuses by following said same procedure, but considering concentrations and doses of said infuses referred upon an aside of concentrations and doses of the invention.
11. (Withdrawn) A fabrication and use of said medication of claim 9, further including a procedure to manufacture said capsicum extract infuses comprising:
- (a) taking 100gr of a fresh plant tissue of chilies, which are washed and soaked in a distilled water, and being dried, and
 - (b) chopping and ground intermittently said fresh plant tissue of chilies in a blender until a homogenous liquid and solid material is obtained, and
 - (c) straining said homogenous liquid and solid material to discard said solid material and obtain a filtrate, and
 - (d) centrifuging at 4 degree centigrades for 30min said filtrate to obtain a supernatant, and
 - (e) collecting and recentrifuging said supernatant to obtain a final supernatant, and
 - (f) testing by high performance liquid chromatography said final supernatant to determine a general pungency in scoville units, and
 - (g) sterilizing by heating said final supernatant inside a large test tube, which may be placed into a boiling water bath, being swirled every 5min and refrigerated after 20min of heating, and

- (h) fabricating a carrier solution which it is elaborated by containing just diluents as mentioned upon the aside of a procedure to prepare a preferred embodiment for capsaicin infuses, and
- (i) diluting a aliquot of said final supernatant by using said carrier solution until 32 scoville units for every 2mcg/ml of said capsaicin contained in intravenous and intramuscular/ subcutaneous infuses to prepare, and
- (j) preserving infuses after they are prepared in sealed containers and refrigeration conditions.

12. (New) A medication for the treatment of a human immunodeficiency virus and an acquired immunodeficiency syndrome wherein natural and synthetic capsaicin infuses are fabricated with concentrations ranging between 2mcg/ml and 80mcg/ml in agreement to a function $f(x) = 1/x$, being diluted said capsaicin in a diluent to a volume ranging between 4 and 75 ml.

13. (New) A medication of claim 12, wherein infuses are fabricated with concentrations ranging between 2mcg/ml and 8mcg/ml, being diluted said capsaicin in a volume of distilled water ranging between 4 and 5ml.

14. (New) A medication of claim 12, wherein infuses are fabricated in concentrations ranging between 10mcg/ml and 80mcg/ml, being diluted said capsaicin in a volume of distilled water ranging between 6 and 75ml.

15. (New) A medication of claim 13, wherein infuses are fabricated with doses ranging between 1mcg/kg bodyweight and 7mcg/kg bodyweight.

16. (New) A medication of claim 14, wherein infuses are fabricated with doses ranging between 1mcg/kg bodyweight and 8 mcg/kg bodyweight.

17. (New) A medication of claim 14, wherein infuses for a pretreatment are fabricated in concentrations ranging between 20mcg/ml and 50mcg/ml and doses ranging 2mcg/kg bodyweight and 5mcg/kg bodyweight.

18. (New) A medication of claim 12, wherein the medication further includes 0.9% of sodium chloride as a diluent.

19. (New) A medication for the treatment of an human immunodeficiency virus and an acquired immunodeficiency syndrome, wherein capsaicin infuses are fabricated according a function $f(x)$

=1/x, which it follows a pattern of an optimum range of concentrations of between 2mcg/ml and 80mcg/ml.

20. (New) A medication of claim 19, wherein capsaicin infuses are fabricated by having an optimum range of concentrations of between 2mcg/ml and 8mcg/ml, and a range of low volume of distilled water between 4ml and 5ml.

21. (New) A medication of claim 19, wherein capsaicin infuses are fabricated by having an optimum range of concentrations of between 10mcg/ml and 80mcg/ml, and a range of high volume of distilled water of between 6ml and 75ml.

22 (New) A medication of claim 20, wherein said capsaicin infuses are fabricated with doses ranging between 1mcg/kg bodyweight and 7mcg/kg bodyweight.

23 (New) A medication of claim 21, wherein said capsaicin infuses are fabricated with doses ranging between 1mcg/kg bodyweight and 8mcg/kg bodyweight.

24. (New) A medication of claim 19, wherein capsaicin infuses for a pretreatment are fabricated with concentrations ranging between 20mcg/ml and 50mcg/ml and doses ranging 2mcg/kg bodyweight and 5mcg/kg bodyweight.

25 (New) A medication of claim 19, wherein the medication further includes 0.9% of sodium chloride as a diluent.